TP53 codon 72 polymorphism is associated with age at onset of glioblastoma

Neurology

Volumn 72, Issue 4, 2009, Pages 332-336

  Hallani, S El ^a   Ducray, F ^a,b,c   Idbaih, A ^a,b   Marie, Y ^a   Boisselier, B ^a   Colin, C ^a   Laigle Donadey, F ^b   Rodero M ^a   Chinot, O ^d   Thillet, J ^a   Hoang Xuan, K ^a,e   Delattre, J Y ^a,e   Sanson, M ^a,b,e  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL NEUROLOGIQUE   (France)

^d TIMONE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ALLELE; ARTICLE; BLOOD SAMPLING; CODON; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; ADOLESCENT; ADULT; AGE; AGED; BLOOD; COMPARATIVE STUDY; GENE FREQUENCY; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; MUTATION;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; CODON; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC VARIATION; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 60549085031     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000341277.74885.ec     Document Type: Article

References (32)

1. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet 2003;361:323-331.
2. Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 2004;16:607-613.
3. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-1100.
4. Idbaih A, Boisselier B, Sanson M, et al. Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. Cancer Genet Cytogenet 2007;176:121-126.
5. Pim D, Banks L. p53 Polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-199.
6. Damin AP, Frazzon AP, Damin DC, et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 2006;30:523-529.
7. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 2005;11:2502-2509.
8. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003;18:377-385.
9. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-234.
10. Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004;13:11-22.
11. Wegman P, Stal O, Askmalm MS, et al. p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 2006;16:347-351.
12. Sousa H, Santos AM, Catarino R, et al. Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. Eur J Cancer Prev 2006;15:362-366.
13. Gadducci A, Di Cristofano C, Zavaglia M, et al. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 2006;26:687-693.
14. Jones JS, Chi X, Gu X, et al. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-5849.
15. Wang LE, Bondy ML, Shen H, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 2004;64: 5560-5563.
16. Malmer B, Feychting M, Lonn S, et al. p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev 2005;14:2220-2223.
17. Parhar P, Ezer R, Shao Y, et al. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res 2005;137:98-103.
18. Idbaih A, Boisselier B, Marie Y, et al. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet 2007;177: 103-107.
19. Lima-Ramos V, Pacheco-Figueiredo L, Costa S, et al. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet 2008;180:14-19.
20. Toyama T, Zhang Z, Nishio M, et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007; 9:R34.
21. Tommiska J, Eerola H, Heinonen M, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005;11:5098-5103.
22. Damin AP, Frazzon AP, Damin DC, et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 2006;30:523-529.
23. Ide F, Kitada M, Sakashita H, et al. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. Am J Pathol 2003;163:1729-1733.
24. Kruger S, Bier A, Engel C, et al. The p53 codon 72 variation is associated with the age of onset of hereditary nonpolyposis colorectal cancer (HNPCC). J Med Genet 2005; 42:769-773.
25. Shen H, Zheng Y, Sturgis EM, et al. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183: 123-130.
26. Gottschlich S, Maune S, Preugschat J, et al. p53 analysis of laryngeal cancer in exon 4 to 9. Anticancer Res 2000;20: 2613-2616.
27. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 geno-type. Carcinogenesis 1995;16:2205-2208.
28. Murata M, Tagawa M, Kimura H, et al. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol 1998;12:577-581.
29. Sung T, Miller DC, Hayes RL, et al. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000;10:249-259.
30. Von Deimling A, Von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26.
31. Ganigi PM, Santosh V, Anandh B, et al. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients Pediatr Neurosurg 2005;41:292-299.
32. Nakamura M, Shimada K, Ishida E, et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol 2007;9:113-123.